UNSPSC 51263305: Carpindolol

This classification denotes a beta-adrenergic blocking agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W8F97XP38W. European Medicines Agency schedules Carpindolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06141MIG. Carpindolol generally arises in the molecular formula C19H28N2O4. The term CARPINDOLOL is an International Non-Proprietary Name or INN. CARPINDOLOL is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix.

Most nations schedule carpindolol under HS 29339990 and SITC 51577. As of Q4 2014, CARPINDOLOL remains the US FDA Preferred Term for this commodity. Carpindolol bears US NLM identifiers UMLS ID C2699124 and NCI Concept Code C76020. SMILES: O(CC(O)CNC(C)(C)C)C1C2C([NH]C(C2)C(=O)OC(C)C)CCC1.

UNSPSC 51263305 Carpindolol, a Commodity code, does not align with the state and local opportunities currently tagged under it. The recent solicitations—a Seminole County, Florida IFB for Naloxone and drug deactivation systems and a Texas Health and Human Services Commission RFI for direct-to-manufacturer prescription programs—address pharmaceutical procurement, distribution, and pharmacy benefit management, not carpindolol specifically. The mismatch suggests either a cataloging error in the source data or a misalignment between the code's nominal scope and how issuing bodies are tagging pharmaceutical and opioid-response procurements. Carpindolol is a beta-blocker pharmaceutical, yet neither opportunity describes acquiring or distributing that drug; instead, they address naloxone (an opioid antagonist used in overdose response) and broader pharmacy program infrastructure.

The code shows minimal relevant recent activity. State and local procurement activity tagged to this code does not meaningfully support business development planning for carpindolol supply or related services. Before pursuing opportunities under this code, clarify whether issuing bodies are using it correctly or whether the pharmaceutical procurement landscape in state and local jurisdictions uses different code assignments for pharmaceutical ingredients and finished drugs.